Ensysce Biosciences, Inc.
ENSC · XNASCIK 1716947fmd_0112X98AKW9ZX42VMBD3VQR71AManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 37 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 4 | 4 | 3 | 2 | 5 | 5 |
| Provision for credit losses | – | – | 0 | (0) | (0) | (0) | – | – |
| Research and development | – | – | 4 | 5 | 20 | 8 | 7 | 10 |
| Selling, general and administrative | – | – | 1 | 19 | – | – | – | – |
| Total operating expenses | 2 | 3 | 6 | 23 | 27 | 13 | 12 | 15 |
| Operating income | (1) | (3) | (2) | (20) | (24) | (11) | (7) | (10) |
| Interest expense | – | – | 1 | 1 | 0 | 0 | 1 | 0 |
| Interest and investment income | 4 | 4 | 1 | – | – | – | – | – |
| Other non-operating income (expense) | – | – | 1 | (9) | 0 | 0 | (1) | 0 |
| Income before taxes | 3 | (1) | 5 | – | – | – | – | – |
| Income tax expense | 1 | 1 | 0 | – | – | – | – | – |
| Net income from continuing operations | 2 | (1) | 4 | – | – | – | – | – |
| Net income | 2 | (1) | 4 | (29) | (24) | (11) | (8) | (10) |
| Net income to common shareholders | (1) | (3) | 0 | (30) | (25) | (11) | (8) | (10) |